The renaissance of antibody
Languages of publication
The ability of human and animal immunological system to generate many hundreds of millions of antibodies with different variable-region domains allows to bind other proteins, peptides and low molecular weight haptens despite the enormous variety of chemical and physical structures that these entities can represent. The prediction of Paul Ehrlich in 1900 an age of 'magic bullet applications in human therapeutics is now being realized. Hybrydoma technology introduced in 1975 was crucial event for immunology and biotechnology, providing large amounts of specific monoclonal antibodies (Mab) for basic research, immunodiagnosis, serotherapy and industrial processes. During last 20 years significant progress has been made in production of Mab or Mab fragments by DNA recombination techniques and expression in bacteria, yeast, mammalian cells and transgenic animals and plants. The rapid isolation of high affinity human Mab from phage display libraries and by immunization of transgenic mice will facilitate the development of therapeutic antibodies. It become also clear that antibodies and antibody fragments are playing increasing contribution not only to pharmaceutical but also to food, cosmetic and chemical industries, as well as to environmental protection.
Publication order reference
E. Walajtys-Rode, Instytut Biologii i Ochrony Srodowiska, Wyzsza Szkola Pedagogiczna, ul. Cegielniana 12, 35-310 Rzeszow, Poland, e-mail: ewlajty@univ. rzeszow.pl